These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22583743)

  • 1. Validation of the Treatment Satisfaction Questionnaire for Medication in patients with cystic fibrosis.
    Regnault A; Balp MM; Kulich K; Viala-Danten M
    J Cyst Fibros; 2012 Dec; 11(6):494-501. PubMed ID: 22583743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection.
    Greenwood J; Schwarz C; Sommerwerck U; Nash EF; Tamm M; Cao W; Mastoridis P; Debonnett L; Hamed K
    Ther Adv Respir Dis; 2017 Jul; 11(7):249-260. PubMed ID: 28614995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment compliance in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection treated with tobramycin inhalation powder: The FREE study.
    Blasi F; Carnovale V; Cimino G; Lucidi V; Salvatore D; Messore B; Bartezaghi M; Muscianisi E; Porpiglia PA;
    Respir Med; 2018 May; 138():88-94. PubMed ID: 29724399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhaled versus nebulised tobramycin: a real world comparison in adult cystic fibrosis (CF).
    Harrison MJ; McCarthy M; Fleming C; Hickey C; Shortt C; Eustace JA; Murphy DM; Plant BJ
    J Cyst Fibros; 2014 Dec; 13(6):692-8. PubMed ID: 24815094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis.
    Somayaji R; Parkins MD
    Ther Deliv; 2015 Feb; 6(2):121-37. PubMed ID: 25690082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Nebulized colistin versus tobramycin in the treatment of chronic Pseudomonas colonization in cystic fibrosis patients].
    Quintana-Gallego E; Lopez-Campos JL; Calero C; Dapena FJ
    Med Clin (Barc); 2014 Jan; 142(2):59-63. PubMed ID: 23369499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tobramycin inhalation powder in cystic fibrosis patients: response by age group.
    Geller DE; Nasr SZ; Piggott S; He E; Angyalosi G; Higgins M
    Respir Care; 2014 Mar; 59(3):388-98. PubMed ID: 23983274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
    Al-Aloul M; Nazareth D; Walshaw M
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
    Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
    N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
    Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C
    Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence.
    Hamed K; Debonnett L
    Ther Adv Respir Dis; 2017 May; 11(5):193-209. PubMed ID: 28470103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Use of inhaled tobramycin in patients with cystic fibrosis].
    Chermenskiĭ AG; Gembitskaia TE
    Ter Arkh; 2010; 82(8):76-8. PubMed ID: 20873251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budget impact model of tobramycin inhalation solution for treatment of Pseudomonas aeruginosa in cystic fibrosis patients.
    Woodward TC; Brown R; Sacco P; Zhang J
    J Med Econ; 2010; 13(3):492-9. PubMed ID: 20670159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
    Parkins MD; Elborn JS
    Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eradication of
    Akkerman-Nijland AM; Yousofi M; Rottier BL; Van der Vaart H; Burgerhof JGM; Frijlink HW; Touw DJ; Koppelman GH; Akkerman OW
    Ther Adv Respir Dis; 2020; 14():1753466620905279. PubMed ID: 32046620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution.
    Sawicki GS; Signorovitch JE; Zhang J; Latremouille-Viau D; von Wartburg M; Wu EQ; Shi L
    Pediatr Pulmonol; 2012 Jan; 47(1):44-52. PubMed ID: 21815282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aerosolized antibiotics in cystic fibrosis: an update.
    Fiel SB
    Expert Rev Respir Med; 2014 Jun; 8(3):305-14. PubMed ID: 24838090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial.
    Ratjen F; Munck A; Kho P; Angyalosi G;
    Thorax; 2010 Apr; 65(4):286-91. PubMed ID: 19996339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher tobramycin concentration and vibrating mesh technology can shorten antibiotic treatment time in cystic fibrosis.
    Coates AL; Denk O; Leung K; Ribeiro N; Chan J; Green M; Martin S; Charron M; Edwardes M; Keller M
    Pediatr Pulmonol; 2011 Apr; 46(4):401-8. PubMed ID: 21438171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tobramycin inhalation powder (Tobi Podhaler) for cystic fibrosis.
    Med Lett Drugs Ther; 2013 Jun; 55(1419):51-2. PubMed ID: 23797798
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.